en.Wedoany.com Reported - On May 6, 2026, Neuralink, the brain-computer interface company founded by Elon Musk, unveiled a major R&D plan, stating it is developing a surgical robot capable of reaching any area of the brain. The ultimate goal is to build a universal neural interface to help address all diseases originating in the brain. The company also stated that the device is currently still in the research phase and has not yet received approval from the U.S. Food and Drug Administration.
"We are building a surgical robot that can reach any area of the brain," the Neuralink R&D team clearly stated in an internal video. "The ultimate goal is to create a universal neural interface to help solve any disease originating from the brain." This marks a fundamental upgrade in the company's technical roadmap—from initially focusing only on restoring motor function in paralyzed patients, to now targeting a revolutionary "whole-brain coverage" medical platform.
The core hardware for realizing this grand blueprint is a next-generation surgical robot codenamed "Merlin." According to disclosures, the robot has been iterated to its second generation, utilizing eight sets of high-resolution cameras working in coordination with an Optical Coherence Tomography system. This allows it to construct a real-time three-dimensional map of brain blood vessels during surgery, accurately identifying and avoiding capillaries. Compared to its predecessor, the R2 robot integrates a five-axis linkage system, enabling the robotic arm to reach virtually any area of the brain at any angle and depth. In terms of speed, it has achieved a leap forward: the first-generation robot took 17 seconds to implant one electrode, whereas now it takes only 1.5 seconds. A single surgery can independently complete the precise implantation of 1024 electrodes, with the accuracy of each electrode controlled at the micron level.
Regarding implant materials, Neuralink has chosen a technical path vastly different from traditional approaches. It has abandoned rigid electrodes in favor of ultra-thin flexible electrodes with a diameter only one-tenth that of a human hair. The R&D team explains that the brain continuously pulsates and shifts slightly with each heartbeat. Long-term implanted rigid electrodes are like steel needles buried in a bowl of soft tofu, cutting surrounding neural tissue with every pulsation. In contrast, flexible electrodes are like extremely fine threads that can bend with the movement of brain tissue, thereby avoiding any damage. These flexible electrode threads require the robot to "sew" them into the cerebral cortex with the rhythm of a "sewing machine," rapidly and precisely.
This strategic shift by Neuralink aims to transform brain-computer interface technology from "functional compensation" for specific symptoms into "disease treatment" that directly acts on physical lesions. The team elaborated internally: "Every problem in the brain has a physical location. Movement disorders and visual restoration correspond to completely different areas; precise intervention is key." This implies that future brain-computer interfaces may no longer be merely assistive tools for restoring mobility in paralyzed patients. Instead, like surgical procedures, they could precisely repair abnormal neural circuits in the brain associated with depression, addiction, Parkinson's disease, and even epilepsy, potentially even restoring sight to the blind. The company believes that future generations looking back on today will find it inconceivable that "someone paralyzed in a car accident could never walk again."
Underpinning this medical ambition is Neuralink's effort to reshape the entire brain-computer interface medical experience. The company is aiming for "tenfold optimization," committed to simplifying complex brain implantation surgeries into a standardized, highly automated, and streamlined process. By optimizing the entire chain from pre-operative preparation to post-operative recovery, the ultimate goal is to make it as safe, fast, and widespread as today's laser vision correction surgery.
In terms of commercialization and clinical application, Neuralink is taking a giant leap from trials toward mass production. Following the first successful implantation of the brain-computer chip N1 into a patient with high-level quadriplegia in early 2024, as of May 2026, over 20 subjects have received the implant. Musk previously announced that the company plans to start large-scale production of brain-computer interface devices in 2026 and advance a highly streamlined, almost fully automated surgical protocol.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
